Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic *Lactobacillus reuteri*

Chunxu Gao,\(^{a,b,d}\) Angela Major,\(^{a}\) David Rendon,\(^{c}\) Monica Lugo,\(^{b,d}\) Vanessa Jackson,\(^{b,d}\) Zhongcheng Shi,\(^{b,d}\) Yuko Mori-Akiyama,\(^{b,d}\) James Versalovic\(^{a,b,d}\)

Departments of Molecular Virology and Microbiology,\(^{a}\) Pathology and Immunology,\(^{b}\) and Obstetrics and Gynecology,\(^{c}\) Baylor College of Medicine, Houston, Texas, USA; Department of Pathology, Texas Children’s Hospital, Houston, Texas, USA

**ABSTRACT** Probiotics and commensal intestinal microbes suppress mammalian cytokine production and intestinal inflammation in various experimental model systems. Limited information exists regarding potential mechanisms of probiotic-mediated immunomodulation *in vivo*. In this report, we demonstrate that specific probiotic strains of *Lactobacillus reuteri* suppress intestinal inflammation in a trinitrobenzene sulfonic acid (TNBS)-induced mouse colitis model. Only strains that possess the *hdc* gene cluster, including the histidine decarboxylase and histidine-histamine antiporter genes, can suppress colitis and mucosal cytokine (interleukin-6 [IL-6] and IL-1β in the colon) gene expression. Suppression of acute colitis in mice was documented by diminished weight loss, colonic injury, serum amyloid A (SAA) protein concentrations, and reduced uptake of [18F]fluorodeoxyglucose ([18F]FDG) in the colon by positron emission tomography (PET). The ability of probiotic *L. reuteri* to suppress colitis depends on the presence of a bacterial histidine decarboxylase gene(s) in the intestinal microbiome, consumption of a histidine-containing diet, and signaling via the histamine H2 receptor (H2R). Collectively, luminal conversion of L-histidine to histamine by *hdc*\(^+\) *L. reuteri* activates H2R, and H2R signaling results in suppression of acute inflammation within the mouse colon.

**IMPORTANCE** Probiotics are microorganisms that when administered in adequate amounts confer beneficial effects on the host. Supplementation with probiotic strains was shown to suppress intestinal inflammation in patients with inflammatory bowel disease and in rodent colitis models. However, the mechanisms of probiosis are not clear. Our current studies suggest that supplementation with *hdc*\(^+\) *L. reuteri*, which can convert L-histidine to histamine in the gut, resulted in suppression of colonic inflammation. These findings link luminal conversion of dietary components (amino acid metabolism) by gut microbes and probiotic-mediated suppression of colonic inflammation. The effective combination of diet, gut bacteria, and host receptor-mediated signaling may result in opportunities for therapeutic microbiology and provide clues for discovery and development of next-generation probiotics.

The incidence and prevalence of pediatric and adult inflammatory bowel diseases (IBDs) have steadily increased with time during recent decades (1–3). Immunomodulatory treatment strategies, including corticosteroids, immunosuppressants, and anti-tumor necrosis factor (anti-TNF) medications continue to dominate the approach to amelioration of chronic intestinal inflammation. Established pharmacological agents target activation of immune cells and cytokine-mediated signaling pathways in human cells. As one example, the proinflammatory cytokine TNF has been a primary target in IBD therapeutics for more than a decade, and delineation of druggable targets in the innate immune system has resulted in dramatic improvements in induction and maintenance therapy of these chronic inflammatory diseases. However, insufficient attention to targets within intestinal microbes may limit progress in IBD therapeutics and may limit our understanding of the systems biology of chronic inflammation.

The intestinal microbiota are dominated by the phyla *Firmicutes* and *Bacteroidetes*, and differences in bacterial composition among the *Firmicutes* have been described in patients with IBD (4). Relative deficiencies of specific intestinal microbes may contribute to lack of microbe-derived anti-inflammatory factors in humans. For example, one commensal bacterial species, *Faecalibacterium prausnitzii*, which can suppress human cytokine production, is present in reduced amounts and often undetectable in patients with Crohn’s disease (5). In addition, manipulation of the gut microbiome might result in new therapeutic strategies. For example, probiotic combinations including lactobacilli and bifidobacteria can suppress inflammation when administered to patients with acute and chronic pouchitis (6). The question remains whether and how host intestinal microbes (e.g., probiotics) contribute to chronic intestinal inflammation.

*Lactobacillus reuteri* is a commensal intestinal firmicute and probiotic that is widely prevalent in the gastrointestinal tracts of diverse avian and mammalian species (7). *L. reuteri* is generally recognized as safe (GRAS) and is considered to be a beneficial microbe that has been used globally as a probiotic for approxi-
mately 2 decades. *L. reuteri* has been reported to suppress proinflammatory cytokines in intestinal epithelial cells (8) and monocytes (9) and intestinal inflammation in different rodent models (8, 10–13). However, the underlying mechanisms are still not clear. A recent pangenomic study showed that human-derived clade II *L. reuteri* strains contained a complete chromosomal *hdc* gene cluster (genes *hdcA*, *hdcB*, and *hdcP*) and the genetic capacity to convert l-histidine to histamine, and this clade could also suppress human TNF production in vitro. In contrast, clade VI strains, which lacked the *hdc* gene cluster in their bacterial chromosomes, failed to suppress human TNF production in vitro in the absence of histamine generation (14). Histamine is considered to be a primary candidate immunomodulin, or immunomodulatory compound, produced by this *Lactobacillus* species. Inactivation of histidine-to-histamine converting capacity by mutagenesis of the histidine decarboxylase gene (*hdcA*) diminished the ability of *hdc*-positive *L. reuteri* strains to suppress production of human TNF *in vitro* (9). The question whether histidine metabolism, particularly the production of histamine by *hdc* † *L. reuteri*, may contribute to the anti-inflammatory effects of this species *in vivo* deserves investigation as a possible gateway to deepening our understanding of microbiome-mediated intestinal immunomodulation (15, 16).

In the present study, we investigated the mechanisms of intestinal immunomodulation by probiotics in a mammalian host. Clade II *L. reuteri* strains can serve as model microbes of the human gut microbiome, and we explored the relative importance of l-histidine metabolism by *hdc* † *L. reuteri* and whether histamine could represent a key signal modulating intestinal immune responses. We demonstrated that microbiome supplementation with *hdc* † *L. reuteri* in a trinitrobenzene sulfonic acid (TNBS)-induced mouse model of colitis resulted in improvement of overall health status, reduction of colonic inflammation, and suppression of proinflammatory cytokine production. Both the histidine-to-histamine converting enzyme, histidine decarboxylase, and dietary l-histidine must be present for probiotic *L. reuteri* to ameliorate colitis in this mouse model. Luminal conversion of the amino acid l-histidine to histamine and signaling via histamine H2 receptor (H2R) are required for maximal suppression of colitis by *L. reuteri*.

**RESULTS**

*hdc* † *L. reuteri* attenuates colonic inflammation *in vivo*. *L. reuteri* clade II strain 6475 (*L. reuteri* 6475) was isolated from a Finnish mother’s breast milk sample (8) and has been used commercially as a probiotic. This *hdc*-positive strain suppresses human TNF production by myeloid cells (9). The TNBS-triggered acute colitis mouse model (17) was selected for evaluation of colitis suppression by intestinal lactobacilli. Adult (8-week-old) female BALB/c mice were fed *L. reuteri* 6475 (see Fig. S1A in the supplemental material) by daily orogastric gavage following acclimatization and at least 5 days prior to TNBS instillation (Fig. 1A). The severity of colitis was evaluated 2 days after TNBS instillation by weight loss (overall health status), Wallace and Ameho scores (macroscopic and microscopic colonic injury) (18–20) (see Fig. S1B), and serum amyloid A (SAA) protein concentrations (biomarker of mucosal inflammation) (21). In colitis-negative control mice that received phosphate-buffered saline (PBS) only, *L. reuteri* 6475 maintained a healthy baseline without any evidence of colitis. In colitis-positive control mice that were challenged with TNBS in the absence of *L. reuteri*, expected results with increased weight loss, Wallace scores, and serum SAA concentrations were observed (Fig. 1B to D), consistent with acute colitis. In contrast, administration of *L. reuteri* 6475 in late-exponential-phase growth attenuated colitis as indicated by significant reductions in weight loss, Wallace scores, and SAA concentrations compared with colitis-positive controls lacking *L. reuteri* 6475 (Fig. 1B to D).

Ameho scores included assessment of histologic evaluation of colitis so that a comprehensive evaluation of colitis could be performed. TNBS instillation (sans *L. reuteri*) caused necrosis extending deeply into the muscularis propria, whereas *L. reuteri* 6475 administration in TNBS-treated mice yielded mild or prominent mucosal or submucosal inflammation with preservation of intact muscularis mucosa and muscularis propria (Fig. 1E and F). These results were consistent with previous findings (19). Other morphological comparisons yielded reduced colon lengths in mice challenged with TNBS compared with *L. reuteri* 6475-treated mice (see Fig. S1C and D in the supplemental material) and healthy control mice receiving PBS only, consistent with previous findings (22, 23).

To extend the findings related to colitis suppression by *hdc* † *L. reuteri*, we introduced a second clade II *hdc* † *L. reuteri* strain, ATCC PTA 4659 (*L. reuteri* 4659), into the same mouse colitis model. Similarly, *L. reuteri* 4659 diminished the weight loss phenotype, reduced Wallace scores, and decreased SAA concentrations, compared with control mice receiving MRS medium only (see Fig. S2 in the supplemental material).

**PET imaging demonstrates the ability of *L. reuteri* 6475 to suppress intestinal inflammation.** In order to visualize anti-inflammatory effects of *L. reuteri* 6475, combined computed tomography (CT)-positron emission tomography (PET) imaging was applied to the TNBS colitis model. Healthy control mice, colitic mice, and *L. reuteri*-treated mice were subjected to live-animal imaging prior to euthanasia (Fig. 2A). [18F]fluorodeoxyglucose ([18F]FDG) has been applied to mouse colitis studies and was used as the tracer compound because immune cells have been shown to increase glucose uptake and phosphorylation after immune activation (24). During colitis, FDG uptake by activated lymphocytes and other immune cells in the colon can be measured by comparing relative intensities of tracer signals by anatomic location. In healthy control mice, FDG signals were mostly detected in the mouse bladder and upper chest region. These sites were proposed to be body sites where increased glucose uptake and metabolism in healthy states have been documented (25). Trace amounts of FDG signals were shown in pericolic areas in the abdomen, indicating low glucose uptake in the colons of healthy mice (Fig. 2B). In colitic control mice, FDG intensities in the mouse abdomen adjacent to the colon were significantly increased (Fig. 2B), indicating increased glucose uptake surrounding or within the colonic mucosa during colitis. *L. reuteri* 6475 administration lowered FDG intensity in the mouse colon compared to colitic controls (Fig. 2B). FDG intensity was also shown in three-dimensional images (see Videos S1 to S3 in the supplemental material). FDG signal changes in different mouse groups were further confirmed by the FDG standardized uptake value (SUV) quantified blindly in the region of interest (ROI) (colon) in each mouse using Inveon Research Workplace software (Fig. 2C), indicating attenuation of colonic inflammation by *L. reuteri*.

---

*Gao et al.*
**A.**

![Timeline Diagram](image)

**B.**

![Box Plot](image)

**C.**

![Scatter Plot](image)

**D.**

![Bar Graph](image)

**E.**

![Histological Images](image)
L. reuteri administration increased microbial hdc gene expression in the intestine. In order to explore whether hdc genes contribute to the anti-inflammatory effects of L. reuteri in vivo, the relative abundances of hdc genes and mRNA were determined by quantitative PCR (qPCR) in mice gavaged with L. reuteri 6475. Our results demonstrated that L. reuteri 6475 administration significantly increased the relative abundance of bacterial hdcA genes in the mouse gut microbiome (Fig. 3A). In terms of mRNA, both hdcA and hdcP gene expression was significantly increased in colonic luminal contents of mice receiving L. reuteri (Fig. 3B and C). These studies indicate a correlation between elevated hdc gene expression via L. reuteri administration and the effect of colitis attenuation. By enhancing the ability of the intestinal microbiome to convert L-histidine to histamine, the gut microbiome was capable of suppressing intestinal inflammation.

Inactivation of the L. reuteri histidine decarboxylase gene diminished its ability to suppress intestinal inflammation. To further investigate the importance of the bacterial histidine decarboxylase gene with respect to intestinal immunomodulation, we explored the anti-inflammatory effects of hdcA within an isogenic mutant and compared with wild-type L. reuteri 6475 using the same TNBS colitis model. The hdcA gene encodes histidine decarboxylase, and the hdcA mutant derived from L. reuteri 6475 does not generate histamine from L-histidine (9). The L. reuteri 6475 hdcA mutant strain was shown to be deficient in terms of colitis suppression in the TNBS colitis mouse model. The hdcA mutant yielded diminished effects in terms of weight loss, Wallace scores, and SAA concentrations (Fig. 4), suggesting that bacterial histidine decarboxylase mediates anti-inflammatory effects via histamine generation. To exclude the possibility that TNBS may adversely affect the function of L. reuteri in the mouse intestine, we performed additional in vitro experiments and found that TNBS did not affect the survival or proliferation of the L. reuteri (wild-type or mutant) strain (see Fig. S3A and B in the supplemental material).

Dietary L-histidine enables hdc+ L. reuteri to suppress intestinal inflammation. In addition to experiments with different L. reuteri strains, the relative importance of dietary L-histidine as the substrate for histamine generation was evaluated by exposing mice to different diets. BALB/c mice were randomly divided into three feeding groups: regular diet containing approximately 0.4% histidine from intact protein sources; defined diet with all essential amino acids except histidine; and a histidine-free diet derived from defined diet with all amino acids except histidine (see Table S1 in the supplemental material).

Mice in each feeding group were gavaged with the same amount of L. reuteri 6475 or MR5 medium only as the control group. Mice receiving L. reuteri 6475 and dietary L-histidine (in regular mouse chow or amino acid defined diet) demonstrated the expected amelioration of colitis by reduced Wallace scores and serum SAA concentrations (Fig. 5A and B). In contrast, when the mice received a histidine-free diet, L. reuteri 6475 yielded diminished effects on colitis attenuation, suggesting that histidine intake is important for the anti-inflammatory activity of L. reuteri 6475.

Dietary deficiency of L-histidine results in weight loss in mice (see Fig. S4A in the supplemental material), as other studies have shown (26), so weight loss was not used as a primary parameter to evaluate colitis severity in this study. To exclude the possibility that the diets per se contributed to colitis development, groups of mice were fed one of the three diets, and none of these mice developed colitis without TNBS instillation (see Fig. S4B). In summary, L-histidine provides the substrate for intestinal L. reuteri to generate histamine in the presence of active histidine decarboxylase.

Activation of H2R is required for anti-inflammatory effects of microbial histamine. Histamine is a biogenic amine that exerts various pathophysiological functions via four receptors (H1R, H2R, H3R, and H4R) (27). The predominant histamine receptors in the intestinal epithelium are H1R and H2R (28). H2R was shown to be expressed in the intestinal epithelium of humans, simians, and mice (28, 29). Immunohistochemical studies show H2R expression in the BALB/c mouse small intestine and colon, with relatively high intensities in the villi and crypts (Fig. 6A). It has been reported previously that H1R activation results in pro-inflammatory effects such as interferon (IFN) production and Th1 cell proliferation, while H2R activation appears to suppress inflammation (27, 30, 31). So, we hypothesized that microbiodependent histamine binds and activates H2R in the intestinal epithelium, thereby mediating its anti-inflammatory effects.

To determine whether H2R activation was required for L. reuteri’s capacity to attenuate colitis in the TNBS model, ranitidine, an H2R-specific antagonist, was used to block H2R activation in the mouse gut. In the TNBS colitis experiment, addition of ranitidine (100 mg/kg of body weight) to mice receiving hdc+ L. reuteri by orogastric gavage diminished the anti-inflammatory effects of L. reuteri 6475, whereas blocking H1R with its specific antagonist pyrilamine lacked such effects (Fig. 6B to D). These findings support the proposition that L. reuteri 6475 attenuates colitis via an H2R-dependent signaling mechanism. To exclude the possibility that ranitidine or pyrilamine may have adversely affected the function of L. reuteri, in vitro assays were performed by adding ranitidine or pyrilamine to bacterial cultures, and neither compound affected the survival or proliferation of L. reuteri 6475 (see Fig. S3C and D in the supplemental material).

L. reuteri administration affects cytokine gene expression in the colon. To investigate the consequences of H2R-mediated anti-inflammatory effects by hdc+ L. reuteri, relative patterns of mucosal gene expression of selected cytokines in the colons of colitis-negative, colitis-positive, and L. reuteri 6475-treated mice were evaluated by qPCR using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal standard (Fig. 7). TNBS instillation significantly increased expression of genes for proinflammatory cytokines interleukin-1β (IL-1β) and IL-6 compared to healthy mice. L. reuteri 6475 treatment of TNBS-challenged mice significantly reduced the relative amounts of mucosal IL-1β and IL-6 gene expression. Other cytokine genes (TNF, IL-10, IL-12, IFN, IL-17, IL-18), and other cytokines were also measured in the colon, but their expression patterns were similar to those in healthy mice.

FIG 1 hdc+ L. reuteri attenuates colonic inflammation in vivo. (A) Time line of the mouse experiments. After 10 days of acclimatization, 8-week-old female BALB/c mice received 5 × 10⁶ CFU of bacteria in MRS or MR5 medium only by orogastric gavage daily for 7 days. Acute colitis was induced by intrarectal instillation of TNBS-ethanol before the sixth gavage, and colitis severity was evaluated in 2 days. (B to D) Weight loss (B), Wallace scores (C), and SAA concentrations (D) of mice challenged with or without TNBS and gavaged with or without L. reuteri 6475. (E and F) Representative microscopic colon images (hematoxylin and eosin stained) (E) and Ameho scores (F) from mice in the healthy control group (MRS/PBS), the colitis control group (MRS/TNBS), and the L. reuteri-treated group (L. reuteri 6475/TNBS).
and IL-23) were examined, but no significant differences between colitic mice and *L. reuteri*-treated mice were detected.

**DISCUSSION**

Probiotic lactobacilli modulate intestinal immune responses by luminal conversion of dietary amino acids into bioactive compounds such as histamine. In the current study, *hdc*+ *L. reuteri* strains protected BALB/c mice in a TNBS-induced colitis model, as indicated by improvement in overall health status and amelioration of the colitis phenotype. The colitis phenotype was evaluated by macroscopic and microscopic evaluation of colonic tissue, serum biomarker quantitation, mucosal cytokine gene expres-

---

**FIG 2** Detection of colitis attenuation by PET imaging. (A) Time line of the PET imaging experiments. Fasted (for 6 h) mice were anesthetized with isoflurane and received 200 µCi [18F]FDG by intraperitoneal (IP) injection. One hour later, these mice received 200 µl MD-Gastroview rectally immediately before scan initiation. Computed tomography (CT) scanning was performed for 10 min followed by PET scanning for 20 min using the Inveon PET-CT multimodality system. Mice were kept sedated during the scanning process by constant isoflurane inhalation. The images were recorded, and FDG standardized uptake values (SUVs) were analyzed blindly using Inveon Research Workplace software. (B) Representative mouse images captured by PET-CT scanning in each group. The color code bar represents FDG signal intensity. (C) Quantification of FDG signals in mouse colon using SUVs in different groups.
sion, and $^{18}$F-FDG live-animal PET imaging. The importance of dietary histidine and the bacterial enzyme histidine decarboxylase was established by mouse model studies. In the absence of dietary L-histidine or a gut microbiome lacking histidine decarboxylase, colitis suppression by probiotic lactobacilli was reduced significantly. Both the substrate amino acid and the enzymatic machinery, histidine decarboxylase, must be present in the intestinal microbiome in order to generate histamine as the bioactive compound. Histamine H2 receptor signaling in the intestinal epithelium is required for probiotic L. reuteri-mediated immunomodulation and colitis suppression. Previously, L. reuteri was shown to suppress H2R-mediated signaling by increasing cyclic AMP (cAMP) production, protein kinase A (PKA) activation, and suppression of extracellular signal-regulated kinase (ERK) (mitogen-activated protein [MAP] kinase) signaling (9). H2R-mediated signaling via cAMP production and protein kinase A (PKA) activation, followed by inhibition of c-Raf and MEK/ERK MAPK signaling, was described in previous studies (9, 32–34).

The same microbe-derived biochemical compound (histamine) can yield different effects in the host depending on the specific type of histamine receptor. Four different G-protein-coupled histamine receptors have been described, and these receptors differ based on downstream signaling pathways and cell type distributions (27). Histamine receptors are widely distributed in the body, and the histamine type 2 receptor (H2R) appears to be enriched in the mammalian gastrointestinal tract (28, 29). H2R was first characterized in the human stomach as an important target for H2R blockers for treatment of peptic ulcer disease by reduction of acid (HCl) secretion (35). In addition to the importance of H2R in gastric physiology, it is becoming apparent that histamine may have an important immunoregulatory role in the intestine. H2R activation results in cAMP-mediated blockade of c-Raf and suppression of MAP kinase signaling by inhibition of ERK phosphorylation (9, 27). Activation of H2R by histamine suppressed IL-12 production by monocytes (36), IFN-γ production by macrophages (37), TNF secretion by mast cells (38), and IL-12 release by immature dendritic cells (39). In vivo studies showed that histamine suppressed both Th1- and Th2-type responses by H2R (30). Lactobacillus rhamnosus, which secretes histamine significantly, suppressed Peyer patch IL-2, IL-4, IL-5, IL-12, TNF-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF) secretion in wild-type but not H2R-deficient mice (31).

These results indicate that the net effect of luminal histamine may be immunosuppressive and anti-inflammatory in the mammalian gastrointestinal tract. Prior studies of the human metag-

**FIG 3** L. reuteri administration increases hdc gene expression in vivo. (A) Relative abundance of hdcA gene in mouse gut microbiome was significantly increased in mice gavaged with L. reuteri 6475 compared to control mice gavaged with MRS. The relative abundance was determined by qPCR and normalized to the bacterial housekeeping gene rpoB. (B and C) Both hdcA (B) and hdcP (C) gene expression levels were significantly increased in colonic luminal contents of mice receiving L. reuteri compared to control mice receiving MRS. The relative gene expression was determined by qPCR and normalized to the bacterial housekeeping gene rpoB. n = 6 per group. ****, P < 0.0001.
enome reported that pathways of histidine biosynthesis (histamine precursor) were diminished in patients with IBD relative to healthy controls (40). These studies highlight the potential importance of microbiome-mediated histidine metabolism and histamine generation as a microbial mechanism for intestinal immunomodulation. Recent evidence suggests that blocking H2R signaling pathways in humans may result in adverse effects and severe intestinal inflammation. Retrospective and prospective clinical studies of newborns have documented significantly increased incidence and mortality from necrotizing enterocolitis (NEC) following exposure to H2R antagonists (41–43). In addition to NEC, studies have reported an increased risk of exacerbations in Crohn’s disease secondary to H2R blocker exposure (44). The histamine receptor H2R appears to be the key receptor on the intestinal epithelium, involved in signaling and immunomodulation after binding microbiome-derived histamine.

The consumption of hdc gene cluster-positive probiotics in the presence of dietary histidine may maximize the potential benefits by resulting in histamine generation only in intestinal regions enriched for histamine H2 receptors. Oral administration of histamine may cause adverse outcomes, but the careful selection of microbes that colonize specific areas of the small or large intestine may maximize histamine H2 receptor signaling in the intestinal epithelium. Conversely, provision of L-histidine in the diet enables luminal conversion and luminal histamine generation by hdc gene cluster-positive microbes. Another consideration is the relative instability of histamine in vivo. Histamine is unstable in vivo and could be quickly metabolized by histamine N-methyltransferase or diamine oxidase (45). Lower concentrations of histamine might be protective, whereas higher concentrations might be detrimental to epithelial protection from infection (27). The continuous production of small amounts of histamine by the gut microbiome may result in suppression of intestinal inflammation. With respect to bacterial genetics of histamine production, the current study did not include an hdcA complementation strain because antibiotic consumption by mice to maintain

FIG 4  Inactivation of the L. reuteri histidine decarboxylase gene diminishes its ability to suppress intestinal inflammation. The anti-inflammatory effects of hdcA within an isogenic mutant which does not produce histamine were compared with those of wild-type L. reuteri 6475 using the TNBS colitis model. The wild-type strain attenuated colitis compared with the medium-control group (MRS/TNBS), whereas the hdcA mutant yielded diminished effects in terms of weight loss (A), Wallace scores (B), and SAA concentrations (C).
antibiotic resistance plasmids may profoundly affect gut microbi- composition. Future generation of hdcA complementation strains by recombineering (46) may remove the requirement for antibiotic selection. Such future genetic strategies would be helpful to confirm whether histidine decarboxylase is essential for suppression of intestinal inflammation by probiotic L. reuteri.

Adverse effects of histamine are likely due to the preponderance of the H1 receptor in the airways (47) and upper gastrointestinal tract. When ingested orally, histamine may cause adverse reactions and symptoms such as pruritus, bronchoconstriction, airway inflammation, and allergic symptoms (48). For this reason, the food and beverage industry has developed active programs to screen for histamine in foodstuffs and contamination by histamine-generating bacteria. H1R is coupled to Gq/11 family proteins, triggering downstream calcium mobilization with pro-inflammatory effects. In addition to H1R, H4R also appears to contribute to respiratory disease symptoms. Classical antihista- mines relieve respiratory tract symptoms by antagonizing H1R and, more recently, H4R (49). H3R is primarily neuronal, highlighting histamine’s role as a potential neurotransmitter. The characterization of the relative distribution of histamine receptors in the gastrointestinal tract and other body sites will facilitate a more complete understanding of the biology of histamine in vivo.

This report highlights the potential importance of luminal conversion and amino acid metabolism in the biology of the intestinal microbiome and host-microbe mutualism. Luminal conversion of amino acids and different classes of nutrients effectively links diet, the gut bacteria, and mammalian intestinal biology. Bacterial amino acid decarboxylases have been reported to convert glutamate to the neurotransmitter gamma-aminobutyric acid (GABA) (50) and tyrosine to tyramine and phenylalanine to the neuromodulatory compound phenethylamine (51). Differences in the relative abundances of pathways involved in amino acid metabolism present in the gut microbiome may contribute to different disease phenotypes in individuals genetically predisposed to IBD or other immune-mediated conditions. Dietary amino acids are potential substrates for a variety of microbial amino acid decarboxylases, and diverse compounds, including biogenic amines, may be produced. These compounds, such as histamine, may have important consequences for mucosal immunity or functioning of the nervous system. Our study indicates that luminal conversion of an amino acid, L-histidine, to histamine by hdcL+ L. reuteri activates H2R and yields anti-inflammatory effects in the mouse colon. This study combined specific cellular elements of the intestinal microbiome, the genes and enzymatic machinery involved in luminal conversion, and the specific receptors involved in receiving microbial signals. These studies could foster the development of new probiotic therapies by facilitating the selection of natural hdc gene cluster-positive strains (or strains with any defined genetic feature contributing to immunomodulation) combined with dietary elements (e.g., amino acids) or enabling genetic engineering of next-generation probiotics by defining specific microbial genes involved in mitigation of intestinal inflammation. By defining mechanisms of microbiome-mediated immunomodulation in the mammalian intestine, bacterial strains and microbial gene databases can be leveraged to identify next-generation probiotics and microbe-derived medicinal compounds for the treatment of chronic inflammatory diseases.

**MATERIALS AND METHODS**

**Bacterial strains and microbiological culture conditions.** L. reuteri ATCC PTA 6475 and its hdcA mutant as described previously (9) were used to colonize the mice. L. reuteri ATCC PTA 4659, isolated from the breast milk of healthy Finnish women, was a gift from BioGaia AB (Stockholm, Sweden). All L. reuteri strains were cultured at 37°C in deMan, Rogosa, Sharpe (MRS) medium (Difco, Franklin Lakes, NJ) in an anaerobic workstation (MACS MG-500; Microbiology International, Frederick, MD) supplied with a mixture of 10% CO2, 10% H2, and 80% N2. Quantitative analysis of bacteria was performed by counting bacterial CFU on an MRS agar plate per milliliter of bacterial culture relative to optical density at 600 nm (OD600) measured by a SmartSpec Plus spectrophotometer (Bio-Rad Laboratories, CA).

**Animals.** Female BALB/c mice (45 days old) were purchased from Harland Laboratories (Houston, TX) and maintained under specific-pathogen-free (SPF) conditions. Mice were kept under filter-top cages (5 mice per cage) and had free access to distilled water and Harlan rodent chow 2918 (default diet) or other diets as described in Table S1 in the supplemental material. All mouse experiments were performed in an SPF animal facility according to an
Institutional Animal Care and Use Committee (IACUC)-approved mouse protocol at Baylor College of Medicine, Houston, TX.

Preparation of bacteria and administration to mice. *L. reuteri* strains and culture conditions were as described above. Bacteria were harvested at exponential phase (5.5 h in MRS medium with an initial OD$_{600}$ of 0.03) and centrifuged at 2,500 × g for 4 min, and bacterial pellets were resuspended in sterile MRS medium for animal feeding. All *L. reuteri* strains were prepared freshly before administration to mice. Each mouse received 5 × 10^9 CFU of bacteria in 0.2 ml MRS or MRS medium alone (medium control) by orogastric gavage at a frequency of once per day for 7 days. In selected experiments, pyrilamine or ranitidine at a dose of 100 mg/kg body weight was added in the bacterial medium to feed mice by orogastric gavage.

Induction of colitis by intrarectal instillation of TNBS. At 6 h before the six orogastric gavages mentioned above, mice preanesthetized by constant isoflurane inhalation were challenged with 5% (wt/vol) TNBS in

**FIG 6** Activation of H2R is required for the anti-inflammatory effects. (A) Immunohistochemistry studies using H2R-specific antibody showed that H2R was expressed in 9-week-old BALB/c mice, with high intensity in the villi and crypts (red arrows). (B to D) Mice that received pyrilamine (Pyr) did not show an effect on the anti-inflammatory effects of *L. reuteri* 6475, while mice that received ranitidine (Ran) showed a diminished ability for *L. reuteri* 6475 to attenuate colitis, as indicated by weight loss (B), Wallace scores (C), and plasma SAA concentrations (D).
H₂O (Sigma-Aldrich, St. Louis, MO) diluted with an equal volume of absolute ethanol intrarectally (4 cm distal to the anus) via catheter (Brain-tree Scientific, USA) at a dose of 100 mg/kg of body weight. Mice were kept head down in a vertical position for 2 min after enema to ensure complete retention of enema in the colon. Mice from respective control groups received PBS at a dose of 100 mg/kg of body weight instead of TNBS.

**Tissue preparations.** Mice were euthanized 48 h after colitis induction. Blood samples were collected from mice via cardiac puncture in blood sample collection tubes with K₂-EDTA (Becton, Dickinson and Company, Franklin Lakes, NJ) centrifuged at 17,000 × g for 10 min at 4°C to isolate plasma, and stored at −80°C until use. The gastrointestinal tract was carefully removed. Colons and ceca were excised, and colon lengths were measured. Luminal contents in the colon were collected, flash frozen immediately in liquid nitrogen, and stored at −80°C until use.

Mouse intestines were fixed in 10% formalin, embedded with paraffin, and sectioned with a microtome at 5 μm. The sectioned tissues were used for immunohistochemistry targeting H2R expression using specific antibody (Alomone Labs, Jerusalem, Israel). In specific experiments, the colon tissue samples located precisely 2 cm above the anal canal were cut into two parts. One part was fixed overnight in 10% formalin and embedded in paraffin. After hematoxylin and eosin staining, slides were examined microscopically and scored blindly by two pathologists according to Ameho criteria (20). Another tissue fragment was stored in RNAlater (Ambion, Austin, TX) and flash frozen immediately in liquid nitrogen for cytokine gene expression analysis.

**Colitis assessment.** Colitis severity was assessed by weight loss, Wallace score, and serum amyloid protein A (SAA) concentrations as described below. Weight loss is calculated by the formula weight loss = (w₁ − w₂)/w₁ × 100%, where w₁ represents mouse body weight before TNBS instillation and w₂ represents mouse body weight at 48 h after colitis induction. Wallace score (see Fig. S1B in the supplemental material), which was used to quantify colonic injury macroscopically on the excised and longitudinally sectioned with a microtome at 5 μm, immediately in liquid nitrogen, and stored at −80°C until use.

Mouse intestines were fixed in 10% formalin, embedded with paraffin, and sectioned with a microtome at 5 μm. The sectioned tissues were used for immunohistochemistry targeting H2R expression using specific antibody (Alomone Labs, Jerusalem, Israel). In specific experiments, the colon tissue samples located precisely 2 cm above the anal canal were cut into two parts. One part was fixed overnight in 10% formalin and embedded in paraffin. After hematoxylin and eosin staining, slides were examined microscopically and scored blindly by two pathologists according to Ameho criteria (20). Another tissue fragment was stored in RNAlater (Ambion, Austin, TX) and flash frozen immediately in liquid nitrogen for cytokine gene expression analysis.

**Colitis assessment.** Colitis severity was assessed by weight loss, Wallace score, and serum amyloid protein A (SAA) concentrations as described below. Weight loss is calculated by the formula weight loss = (w₁ − w₂)/w₁ × 100%, where w₁ represents mouse body weight before TNBS instillation and w₂ represents mouse body weight at 48 h after colitis induction. Wallace score (see Fig. S1B in the supplemental material), which was used to quantify colonic injury macroscopically on the excised and longitudinally sectioned with a microtome at 5 μm, immediately in liquid nitrogen, and stored at −80°C until use.

**Colitis assessment.** Colitis severity was assessed by weight loss, Wallace score, and serum amyloid protein A (SAA) concentrations as described below. Weight loss is calculated by the formula weight loss = (w₁ − w₂)/w₁ × 100%, where w₁ represents mouse body weight before TNBS instillation and w₂ represents mouse body weight at 48 h after colitis induction. Wallace score (see Fig. S1B in the supplemental material), which was used to quantify colonic injury macroscopically on the excised and longitudinally sectioned with a microtome at 5 μm, immediately in liquid nitrogen, and stored at −80°C until use.

**Colitis assessment.** Colitis severity was assessed by weight loss, Wallace score, and serum amyloid protein A (SAA) concentrations as described below. Weight loss is calculated by the formula weight loss = (w₁ − w₂)/w₁ × 100%, where w₁ represents mouse body weight before TNBS instillation and w₂ represents mouse body weight at 48 h after colitis induction. Wallace score (see Fig. S1B in the supplemental material), which was used to quantify colonic injury macroscopically on the excised and longitudinally sectioned with a microtome at 5 μm, immediately in liquid nitrogen, and stored at −80°C until use.
L. reuteri-Derived Histamine and Colitis Attenuation

Statistical analysis. Biostatistical analyses were performed using GraphPad Prism (version 5) software (GraphPad Inc., La Jolla, CA). For numeric variables that fit normal distribution (determined using the Kolmogorov-Smirnov test), data were presented as means with standard errors, and different groups were compared with the t test (two groups) or one-way analysis of variance (ANOVA) (more than two groups). Otherwise, data were presented as box-and-whisker plots showing the median and 10th and 90th percentiles or scatter plots, and different groups were compared with the nonparamann Mann-Whitney U test (two groups) or the Kruskal-Wallis test (more than two groups). Differences between the groups were considered significant at P < 0.05 (**), P < 0.01 (***), P < 0.001 (****), and P < 0.0001 (*****).

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01358-15/-/DCSupplemental.

REFERENCES
We thank Eamonn Connolly (BioGaia AB, Stockholm) for providing the L. reuteri strains, Toni-Anne Mistretta and Bhanu Priya Ganesh for assistance with data plotting and statistical analysis, and Coreen Johnson for guidance, designed the experiments, and wrote the manuscript.

This work was supported by the National Institutes of Health (R01 AT004326, UH3 DK083990, and U01 CA170930) and the National Institutes of Health (National Institute for Diabetes and Digestive and Kidney Diseases)-funded Texas Medical Center Digestive Diseases Center (DK56338) (J.V.).

We thank Samuel Gelfand (Texas Children’s Hospital) for the use of the Small Animal Imaging Facility and especially Caterina Kaffes and M. Waleed for assistance with bacterial DNA and RNA extractions from luminal contents. We thank Texas Children’s Hospital for the use of the Small Animal Imaging Facility and especially Caterina Kaffes and M. Waleed Gaber for PET imaging.

We disclose the following: J.V. receives unrestricted research support from BioGaia AB. The remaining authors disclose no conflicts.

The remaining authors disclose no conflicts.

ACKNOWLEDGMENTS

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46–54. http://dx.doi.org/10.1053/j.gastro.2011.10.001.

2. Moradkhani A, Beckman LJ, Tabibian JH. 2013. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis 7:467–473. http://dx.doi.org/10.1093/jcc/djs107.

3. Benchimol EI, To T, Griffiths AM, Rabeneck L, Guttmann A. 2011. Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universal-access healthcare system. J Pediatr 158:960–967. http://dx.doi.org/10.1016/j.jpeds.2010.11.039.

4. Knights D, Lassen KC, Xavier RJ. 2013. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62:1505–1510. http://dx.doi.org/10.1136/gutjnl-2012-303954.

5. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Bluegon S, Brionneau C, Furet JP, Corthier G, Granger C, Vasquez N, Pochart P, Grangeon Y, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Angenot L, Lepage C, Vaessen P, Casellas P. 2007. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736. http://dx.doi.org/10.1073/pnas.0808481105.

6. Gionchetti P, Rizzello F, Venturi A, Bridi P, Matteuzzi D, Bazzocchi G, Poglioli G, Miglioli M, Campieri M. 2000. Oral bacterial therapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309. http://dx.doi.org/10.1053/gast.2000.9370.

7. Casas IA, Dobrogosz WJ. 2000. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis 12:247–285. http://dx.doi.org/10.1080/089106000500216246-1.

8. Liu Y, Fatethere NY, Mangalat N, Rhodes JM. 2010. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299:G1087–G1096. http://dx.doi.org/10.1152/ajpgi.00124.2010.

9. Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, Britton RA, Kalkum M, Versalovic J. 2012. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One 7:e31951. http://dx.doi.org/10.1371/journal.pone.0031951.

10. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. 1999. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107–1114. http://dx.doi.org/10.1016/S0016-5085(99)70013-2.

11. Pena JA, Li SY, Wilson PH, Thibodeau SA, Szyj A, Versalovic J. 2004. Genotypic and phenotypic studies of murine intestinal lactobacilli species differences in mice with and without colitis. Appl Environ Microbiol 70:558–568. http://dx.doi.org/10.1128/AEM.70.1.558-568.2004.

12. Schreiber O, Petersson J, Phillipsen M, Perry M, Roos S, Holm L. 2009. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte- and platelet-endothelial cell interactions. Am J Physiol Gastrointest Liver Physiol 296:G534–G542. http://dx.doi.org/10.1152/ajpgi.049470.2008.

13. Preidis GA, Saulnier DM, Blutt SE, Mistretta T, Richie KP, Major AM, Venable SF, Barrish JP, Finegold MJ, Petrossino JF, Guerlant RL, Conner ME, Versalovic J. 2012. Host response to probiotics determined by nutritional status of rotavirus-infected neonatal mice. J Pediatr Gastroenterol Nutr 53:299–307. http://dx.doi.org/10.1097/MJP.0b013e31824d2548.

14. Spinder JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DMA, Mistretta TA, Devaraj S, Walter J, Versalovic J, Highlander SK. 2014. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol 6:1772–1789. http://dx.doi.org/10.1093/gbe/evu137.

15. Preidis GA, Versalovic J. 2009. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastrointestinal enteroga with the metagenomics era. Gastroenterology 136:2015–2031. http://dx.doi.org/10.1053/j.gastro.2009.01.072.

16. Hemarajata P, Gao C, Pughfoehl KJ, Thomas CM, Saulnier DM, Spinder JK, Versalovic J. 2013. Lactobacillus reuteri-specific immunoregulatory gene rrsR modulates histamine production and immunomodulation by Lactobacillus reuteri. J Bacteriol 195:5567–5576. http://dx.doi.org/10.1128/JB.00261-13.

17. Scheiffele F, Fuss JJ. 2002. Induction of TNBS colitis in mice. Curr Protec Immunol Commun 15:Unit 15.19. http://dx.doi.org/10.1002/1071-1472(200207)15:191.</p>
Increased serum amyloid A levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. Cytokine 12:1337–1347. http:// dx.doi.org/10.1006/cyto.2000.0716.

22. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568–G576. http://dx.doi.org/10.1152/ajpgi.00329.2010.

23. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Pianowski LF, Calixto JB. 2011. Preventive and therapeutic euphori treatment attenuates experimental colitis in mice. PLoS One 6:e27122. http://dx.doi.org/10.1371/journal.pone.0027122.

24. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Gao et al. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568–G576. http://dx.doi.org/10.1152/ajpgi.00329.2010.

23. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Pianowski LF, Calixto JB. 2011. Preventive and therapeutic euphori treatment attenuates experimental colitis in mice. PLoS One 6:e27122. http://dx.doi.org/10.1371/journal.pone.0027122.

24. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Gao et al. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568–G576. http://dx.doi.org/10.1152/ajpgi.00329.2010.

23. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Pianowski LF, Calixto JB. 2011. Preventive and therapeutic euphori treatment attenuates experimental colitis in mice. PLoS One 6:e27122. http://dx.doi.org/10.1371/journal.pone.0027122.

24. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Gao et al. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568–G576. http://dx.doi.org/10.1152/ajpgi.00329.2010.

23. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Pianowski LF, Calixto JB. 2011. Preventive and therapeutic euphori treatment attenuates experimental colitis in mice. PLoS One 6:e27122. http://dx.doi.org/10.1371/journal.pone.0027122.

24. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Gao et al. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568–G576. http://dx.doi.org/10.1152/ajpgi.00329.2010.

23. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Pianowski LF, Calixto JB. 2011. Preventive and therapeutic euphori treatment attenuates experimental colitis in mice. PLoS One 6:e27122. http://dx.doi.org/10.1371/journal.pone.0027122.

24. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Gao et al. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568–G576. http://dx.doi.org/10.1152/ajpgi.00329.2010.